Clinical Trial Update: Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma [Phase 1]

View source ↗

Summary

Phase 1 study update for VAY736 in non-Hodgkin lymphoma shows the trial status as terminated, evaluating VAY736 alone and in combination with other antineoplast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• VAY736

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma | Phase 1 | Status: TERMINATED